Search - tctmd.com

Displaying 21 - 40 of 116

Sort: Relevancy | Date

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

Transcatheter Edge-to-Edge Repair Shows Benefit in Moderate MR

News Conference News NY Valves 2024

Transcatheter Edge-to-Edge Repair Shows Benefit in Moderate MR

Michael O'Riordan

June 10, 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

News Conference News ESC Heart Failure 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

Michael O'Riordan

May 21, 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

News Conference News ESC Heart Failure 2024

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

Michael O'Riordan

May 13, 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

April 07, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

November 14, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

News Conference News ESC 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

September 01, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

News Conference News ESC Heart Failure 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

June 06, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.